These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32142951)

  • 1. Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China.
    Islam MM; Tan Y; Hameed HMA; Liu Y; Chhotaray C; Cai X; Liu Z; Lu Z; Wang S; Cai X; Su B; Li X; Tan S; Liu J; Zhang T
    J Glob Antimicrob Resist; 2020 Sep; 22():290-295. PubMed ID: 32142951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
    Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
    BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.
    Kambli P; Ajbani K; Nikam C; Sadani M; Shetty A; Udwadia Z; Georghiou SB; Rodwell TC; Catanzaro A; Rodrigues C
    Int J Mycobacteriol; 2016 Mar; 5(1):1-6. PubMed ID: 26927983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China.
    Du Q; Dai G; Long Q; Yu X; Dong L; Huang H; Xie J
    Diagn Microbiol Infect Dis; 2013 Oct; 77(2):138-42. PubMed ID: 23948547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA expression analysis of efflux pump genes in clinical isolates of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in South Korea.
    Oh TS; Kim YJ; Kang HY; Kim CK; Cho SY; Lee HJ
    Infect Genet Evol; 2017 Apr; 49():111-115. PubMed ID: 28062386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand.
    Sowajassatakul A; Prammananan T; Chaiprasert A; Phunpruch S
    BMC Microbiol; 2014 Jun; 14():165. PubMed ID: 24953243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China.
    Zhang Z; Liu M; Wang Y; Pang Y; Kam KM; Zhao Y
    Eur J Clin Microbiol Infect Dis; 2014 Nov; 33(11):1959-66. PubMed ID: 24906439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China.
    Hu Y; Hoffner S; Wu L; Zhao Q; Jiang W; Xu B
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3857-63. PubMed ID: 23733477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).
    Kateete DP; Kamulegeya R; Kigozi E; Katabazi FA; Lukoye D; Sebit SI; Abdi H; Arube P; Kasule GW; Musisi K; Dlamini MG; Khumalo D; Joloba ML
    BMC Pulm Med; 2019 Jul; 19(1):124. PubMed ID: 31291943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene.
    Jugheli L; Bzekalava N; de Rijk P; Fissette K; Portaels F; Rigouts L
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5064-8. PubMed ID: 19752274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characterization of Resistance to Second-Line Anti-Mycobacterial Drugs among Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis.
    Habibnia S; Karami-Zarandi M; Zaker S; Ghalavand Z; Doustdar F; Eslami G; Kazemian H
    Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.
    Brossier F; Pham A; Bernard C; Aubry A; Jarlier V; Veziris N; Sougakoff W;
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant
    Varghese B; Al-Hajoj S
    Am J Trop Med Hyg; 2017 May; 96(5):1066-1070. PubMed ID: 28500800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort.
    Syed RR; Catanzaro DG; Colman RE; Cooney CG; Linger Y; Kukhtin AV; Holmberg RC; Norville R; Crudu V; Ciobanu N; Codreanu A; Seifert M; Hillery N; Chiles P; Catanzaro A; Rodwell TC
    J Clin Microbiol; 2023 Mar; 61(3):e0147822. PubMed ID: 36757183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review.
    Georghiou SB; Magana M; Garfein RS; Catanzaro DG; Catanzaro A; Rodwell TC
    PLoS One; 2012; 7(3):e33275. PubMed ID: 22479378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis.
    Reeves AZ; Campbell PJ; Willby MJ; Posey JE
    Antimicrob Agents Chemother; 2015 Jan; 59(1):444-9. PubMed ID: 25385119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redefining MDR-TB: Comparison of Mycobacterium tuberculosis clinical isolates from Russia and Taiwan.
    Jou R; Lee WT; Kulagina EV; Weng JY; Isakova AI; Lin WH; Antonova OV; Wu MH; Arslanbaeva LR; Tasi HY; Nosova EY; Zimenkov DV
    Infect Genet Evol; 2019 Aug; 72():141-146. PubMed ID: 30593924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
    Engström A; Perskvist N; Werngren J; Hoffner SE; Juréen P
    J Antimicrob Chemother; 2011 Jun; 66(6):1247-54. PubMed ID: 21427106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing.
    Chakravorty S; Lee JS; Cho EJ; Roh SS; Smith LE; Lee J; Kim CT; Via LE; Cho SN; Barry CE; Alland D
    J Clin Microbiol; 2015 Jan; 53(1):43-51. PubMed ID: 25339395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study.
    Conkle-Gutierrez D; Kim C; Ramirez-Busby SM; Modlin SJ; Mansjö M; Werngren J; Rigouts L; Hoffner SE; Valafar F
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0207521. PubMed ID: 35532237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.